ES2870920T3 - Inhibidores de CXCR4 y usos de los mismos - Google Patents
Inhibidores de CXCR4 y usos de los mismos Download PDFInfo
- Publication number
- ES2870920T3 ES2870920T3 ES17816163T ES17816163T ES2870920T3 ES 2870920 T3 ES2870920 T3 ES 2870920T3 ES 17816163 T ES17816163 T ES 17816163T ES 17816163 T ES17816163 T ES 17816163T ES 2870920 T3 ES2870920 T3 ES 2870920T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- optionally substituted
- membered
- nitrogen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC(CC*1)N1C(CC)C1C*CC1 Chemical compound CCCC(CC*1)N1C(CC)C1C*CC1 0.000 description 16
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VICYTAYPKBLQFB-UHFFFAOYSA-N CCOC(C(CBr)=O)=O Chemical compound CCOC(C(CBr)=O)=O VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
- UMRZSTCPUPJPOJ-UHFFFAOYSA-N C(C1)C2CC1CC2 Chemical compound C(C1)C2CC1CC2 UMRZSTCPUPJPOJ-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N C(C1)C2CCN1CC2 Chemical compound C(C1)C2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- ASUQYWCXZRNVRW-UHFFFAOYSA-N C(C1)C2CCNC1C2 Chemical compound C(C1)C2CCNC1C2 ASUQYWCXZRNVRW-UHFFFAOYSA-N 0.000 description 1
- GYLMCBOAXJVARF-UHFFFAOYSA-N C(C1)C2CNC1C2 Chemical compound C(C1)C2CNC1C2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 1
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N C(C1)C2CNC1CC2 Chemical compound C(C1)C2CNC1CC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 1
- GMOFDANHMUHNBP-UHFFFAOYSA-N C(C1)C2CSC1CC2 Chemical compound C(C1)C2CSC1CC2 GMOFDANHMUHNBP-UHFFFAOYSA-N 0.000 description 1
- SNZSSCZJMVIOCR-UHFFFAOYSA-N C(C1)C2NC1CC2 Chemical compound C(C1)C2NC1CC2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N C(C1)C2NC1CNC2 Chemical compound C(C1)C2NC1CNC2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- MNILDQSRDHCFJG-UHFFFAOYSA-N C(C1)C2NC1COC2 Chemical compound C(C1)C2NC1COC2 MNILDQSRDHCFJG-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N C(C1)C2OC1CNC2 Chemical compound C(C1)C2OC1CNC2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- NKFZUGIEJYGXMY-UHFFFAOYSA-N C(C1)C2OC1OC2 Chemical compound C(C1)C2OC1OC2 NKFZUGIEJYGXMY-UHFFFAOYSA-N 0.000 description 1
- PGRMVFYQFHCNSA-UHFFFAOYSA-N C(C1)C2OCCN1C2 Chemical compound C(C1)C2OCCN1C2 PGRMVFYQFHCNSA-UHFFFAOYSA-N 0.000 description 1
- ORCQJRXQASSNAQ-UHFFFAOYSA-N C(C1)C2c3ccccc3C1CC2 Chemical compound C(C1)C2c3ccccc3C1CC2 ORCQJRXQASSNAQ-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N C(C1)CN2C1CNCC2 Chemical compound C(C1)CN2C1CNCC2 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- VLCAUFUDKLGTBG-UHFFFAOYSA-N C(C12)=CC=CC1=C1OC=C2C=C1 Chemical compound C(C12)=CC=CC1=C1OC=C2C=C1 VLCAUFUDKLGTBG-UHFFFAOYSA-N 0.000 description 1
- YVPKKTHVFYAAQN-UHFFFAOYSA-N C1=CN=[I]N=C1 Chemical compound C1=CN=[I]N=C1 YVPKKTHVFYAAQN-UHFFFAOYSA-N 0.000 description 1
- WFKDDADPNCMDCZ-UHFFFAOYSA-N C1C(C=C2)=COC2=C1 Chemical compound C1C(C=C2)=COC2=C1 WFKDDADPNCMDCZ-UHFFFAOYSA-N 0.000 description 1
- YVHBSYTYLQYTOU-UHFFFAOYSA-N C1C2NC1CNC2 Chemical compound C1C2NC1CNC2 YVHBSYTYLQYTOU-UHFFFAOYSA-N 0.000 description 1
- UKHJNJFJCGBKSF-UHFFFAOYSA-N C1C2NCC1NC2 Chemical compound C1C2NCC1NC2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 description 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N C1C2OCC1NC2 Chemical compound C1C2OCC1NC2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- VJKNAEZWNVUHAF-VQTJNVASSA-N CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl VJKNAEZWNVUHAF-VQTJNVASSA-N 0.000 description 1
- CTKHJJPOGHSDRV-VQTJNVASSA-N CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2F Chemical compound CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2F CTKHJJPOGHSDRV-VQTJNVASSA-N 0.000 description 1
- ZFJYNKPPNRBFTH-FCHUYYIVSA-N CC(C)N(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C)cccn3)c(CO)[n]12 Chemical compound CC(C)N(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C)cccn3)c(CO)[n]12 ZFJYNKPPNRBFTH-FCHUYYIVSA-N 0.000 description 1
- SIZPIHICIYHVJQ-PKTZIBPZSA-N CC(C)N([C@H](CCC1)c2c[n]3c(N4CCN(C)CC4)cccc3n2)[C@@H]1c1c(C)cccn1 Chemical compound CC(C)N([C@H](CCC1)c2c[n]3c(N4CCN(C)CC4)cccc3n2)[C@@H]1c1c(C)cccn1 SIZPIHICIYHVJQ-PKTZIBPZSA-N 0.000 description 1
- KOMFSHQSMBSMKX-PKTZIBPZSA-N CC(C)c1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound CC(C)c1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 KOMFSHQSMBSMKX-PKTZIBPZSA-N 0.000 description 1
- ASIBQPPRHGMYRV-UHFFFAOYSA-N CC(CC=C1)NC1=N Chemical compound CC(CC=C1)NC1=N ASIBQPPRHGMYRV-UHFFFAOYSA-N 0.000 description 1
- HXVSCNSWQUNVQU-NRRUETGQSA-N CC(N([C@@H]1CCC2)[C@@H]2c2c(C)cccn2)[ClH]c2c1nc1[n]2c(N2CCN(C)CC2)ccc1 Chemical compound CC(N([C@@H]1CCC2)[C@@H]2c2c(C)cccn2)[ClH]c2c1nc1[n]2c(N2CCN(C)CC2)ccc1 HXVSCNSWQUNVQU-NRRUETGQSA-N 0.000 description 1
- RMTXSHIMDOGRNW-QFXXITGJSA-N CC/C=N/C/C=C/C Chemical compound CC/C=N/C/C=C/C RMTXSHIMDOGRNW-QFXXITGJSA-N 0.000 description 1
- PIPWSBOFSUJCCO-UHFFFAOYSA-N CC1(C)NCCNC1 Chemical compound CC1(C)NCCNC1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 description 1
- DWARBTVEMLZQCW-SAOADBDPSA-N CC1N2C(N(CC3)CCN3C3CCOCC3)=CC=CC2=NC1[C@@H](CCC1)N(C)[C@@H]1c1c(C)cccn1 Chemical compound CC1N2C(N(CC3)CCN3C3CCOCC3)=CC=CC2=NC1[C@@H](CCC1)N(C)[C@@H]1c1c(C)cccn1 DWARBTVEMLZQCW-SAOADBDPSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N CC1NCCNC1 Chemical compound CC1NCCNC1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- MHASERYOVSJGAR-RBUKOAKNSA-N CCN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CCN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl MHASERYOVSJGAR-RBUKOAKNSA-N 0.000 description 1
- RFPBBQHDUGKCKW-LOSJGSFVSA-N CCN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(C)C)cccn3)c(COCC)[n]12 Chemical compound CCN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(C)C)cccn3)c(COCC)[n]12 RFPBBQHDUGKCKW-LOSJGSFVSA-N 0.000 description 1
- OBARYTISHKVXKC-UHFFFAOYSA-N CCNCCNCCCCC(C)(C)C Chemical compound CCNCCNCCCCC(C)(C)C OBARYTISHKVXKC-UHFFFAOYSA-N 0.000 description 1
- BJTUQUWXNCMQGA-UHFFFAOYSA-N CCOC(c(nc1[n]2c(Br)ccc1)c2F)=O Chemical compound CCOC(c(nc1[n]2c(Br)ccc1)c2F)=O BJTUQUWXNCMQGA-UHFFFAOYSA-N 0.000 description 1
- VJMNOJHFYDPFKP-UHFFFAOYSA-N CCOC(c1c[n]2c(Br)cccc2n1)=O Chemical compound CCOC(c1c[n]2c(Br)cccc2n1)=O VJMNOJHFYDPFKP-UHFFFAOYSA-N 0.000 description 1
- KDXGNSFLTHLKHA-BJKOFHAPSA-N CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C(C)C)ccc2 Chemical compound CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C(C)C)ccc2 KDXGNSFLTHLKHA-BJKOFHAPSA-N 0.000 description 1
- KXPSPKWWKRKKSH-BJKOFHAPSA-N CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C1CC1)ccc2 Chemical compound CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C1CC1)ccc2 KXPSPKWWKRKKSH-BJKOFHAPSA-N 0.000 description 1
- QLXRANTXWNPMIO-ZYKFHVCXSA-N CN(C(CC1)C2)C1CN2c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 Chemical compound CN(C(CC1)C2)C1CN2c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 QLXRANTXWNPMIO-ZYKFHVCXSA-N 0.000 description 1
- KCZBSPPSZWKMOE-VQTJNVASSA-N CN(C)C(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CN(C)C(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl KCZBSPPSZWKMOE-VQTJNVASSA-N 0.000 description 1
- NRQSICPUUTWMEP-VQTJNVASSA-N CN(C)C(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 Chemical compound CN(C)C(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 NRQSICPUUTWMEP-VQTJNVASSA-N 0.000 description 1
- QSPATAVPZRFHKY-ZWKOTPCHSA-N CN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c1c(C(F)(F)F)cccn1)c2F Chemical compound CN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c1c(C(F)(F)F)cccn1)c2F QSPATAVPZRFHKY-ZWKOTPCHSA-N 0.000 description 1
- QRHFTFJGHOVZHY-VQTJNVASSA-N CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(F)(F)F)cccn3)c(COC)[n]12 Chemical compound CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(F)(F)F)cccn3)c(COC)[n]12 QRHFTFJGHOVZHY-VQTJNVASSA-N 0.000 description 1
- HTKVSXNFPSPXKF-ZWKOTPCHSA-N CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 Chemical compound CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 HTKVSXNFPSPXKF-ZWKOTPCHSA-N 0.000 description 1
- JSYZRETYSXDPFW-ZYKFHVCXSA-N CN(CC1CC2)CC2N1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 Chemical compound CN(CC1CC2)CC2N1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 JSYZRETYSXDPFW-ZYKFHVCXSA-N 0.000 description 1
- GGACZVMYUPYTQX-GFULKKFKSA-N Cc1c(/C=C/C(/C=C/c(nc2[n]3cccc2)c3N2CCN(C)CC2)=O)nccc1 Chemical compound Cc1c(/C=C/C(/C=C/c(nc2[n]3cccc2)c3N2CCN(C)CC2)=O)nccc1 GGACZVMYUPYTQX-GFULKKFKSA-N 0.000 description 1
- JPLKJAFZEDVAAE-UHFFFAOYSA-N Cc1c(C(CC(C2)=O)N(C)C2c2c[n]3c(N4CCNCC4)cccc3n2)nccc1 Chemical compound Cc1c(C(CC(C2)=O)N(C)C2c2c[n]3c(N4CCNCC4)cccc3n2)nccc1 JPLKJAFZEDVAAE-UHFFFAOYSA-N 0.000 description 1
- DZYAFPAMOAKYQL-MOPGFXCFSA-N Cc1c([C@@H](CCC2)N(C)[C@@H]2c(nc2[n]3c(N4CCN(C)CC4)ccc2)c3Cl)nccc1 Chemical compound Cc1c([C@@H](CCC2)N(C)[C@@H]2c(nc2[n]3c(N4CCN(C)CC4)ccc2)c3Cl)nccc1 DZYAFPAMOAKYQL-MOPGFXCFSA-N 0.000 description 1
- XCHCGSNKJCUYBM-LEWJYISDSA-N Cc1c([C@@H](CCC2)N(C)[C@@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound Cc1c([C@@H](CCC2)N(C)[C@@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 XCHCGSNKJCUYBM-LEWJYISDSA-N 0.000 description 1
- PGLOSMWHIGEBJH-PKTZIBPZSA-N Cc1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N(CC4)CCN4C4COC4)cccc3n2)nccc1 Chemical compound Cc1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N(CC4)CCN4C4COC4)cccc3n2)nccc1 PGLOSMWHIGEBJH-PKTZIBPZSA-N 0.000 description 1
- URBDHSGAUQCNMX-PKTZIBPZSA-N Cc1c([C@H](CCC2)N(CCCO)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound Cc1c([C@H](CCC2)N(CCCO)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 URBDHSGAUQCNMX-PKTZIBPZSA-N 0.000 description 1
- YTVPPFLXRJAVSJ-DFIYOIEZSA-N Cc1c([C@H](CCC[C@@H]23)N2O[C@@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 Chemical compound Cc1c([C@H](CCC[C@@H]23)N2O[C@@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 YTVPPFLXRJAVSJ-DFIYOIEZSA-N 0.000 description 1
- YTVPPFLXRJAVSJ-WZOHSFFVSA-N Cc1c([C@H](CCC[C@@H]23)N2O[C@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 Chemical compound Cc1c([C@H](CCC[C@@H]23)N2O[C@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 YTVPPFLXRJAVSJ-WZOHSFFVSA-N 0.000 description 1
- RKGVLRIDAMKDLF-UHFFFAOYSA-N Cc1c[n]2c(N3CCN(C)CC3)c(C(CC(C3)=O)NC3c3c(C)cccn3)nc2cc1 Chemical compound Cc1c[n]2c(N3CCN(C)CC3)c(C(CC(C3)=O)NC3c3c(C)cccn3)nc2cc1 RKGVLRIDAMKDLF-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N FC1(CCNCC1)F Chemical compound FC1(CCNCC1)F MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N Nc1nc(Br)ccc1 Chemical compound Nc1nc(Br)ccc1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352820P | 2016-06-21 | 2016-06-21 | |
| US201762456526P | 2017-02-08 | 2017-02-08 | |
| PCT/US2017/038609 WO2017223239A1 (en) | 2016-06-21 | 2017-06-21 | Cxcr4 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2870920T3 true ES2870920T3 (es) | 2021-10-28 |
Family
ID=60783547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17816163T Active ES2870920T3 (es) | 2016-06-21 | 2017-06-21 | Inhibidores de CXCR4 y usos de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10759796B2 (https=) |
| EP (2) | EP3808748A1 (https=) |
| JP (2) | JP7054529B2 (https=) |
| CN (2) | CN116554168B (https=) |
| CA (1) | CA3027498A1 (https=) |
| ES (1) | ES2870920T3 (https=) |
| WO (1) | WO2017223239A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| PL3393468T3 (pl) | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| EP3585387A4 (en) | 2017-02-21 | 2020-08-12 | Emory University | CHEMIOKIN CXCR4 RECEIVER MODULATORS AND THEIR USES |
| US11649235B2 (en) | 2018-03-19 | 2023-05-16 | Emory University | Pan-tropic entry inhibitors |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CN114206869A (zh) * | 2019-06-26 | 2022-03-18 | X4 制药有限公司 | Cxcr4抑制剂和其用途 |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| KR20220071223A (ko) | 2019-09-30 | 2022-05-31 | 닛뽕 케미파 가부시키가이샤 | 아제판 유도체 |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| WO2021263203A1 (en) * | 2020-06-26 | 2021-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| EP4444304A4 (en) * | 2021-12-09 | 2025-12-17 | X4 Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF PRIMARY IMMUNE DISCOMFORT |
| US20250326753A1 (en) * | 2022-03-25 | 2025-10-23 | X4 Pharmaceuticals, Inc. | Dual cxcr4-btk inhibitors |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
| JP2026502774A (ja) * | 2022-10-26 | 2026-01-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 神経疾患の処置のためのｃｘｃｒ４阻害剤 |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9200245D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US5235056A (en) | 1992-04-22 | 1993-08-10 | Ciba-Geigy Corporation | Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| WO1997009976A2 (en) | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
| PL329070A1 (en) | 1996-03-22 | 1999-03-15 | Du Pont Pharm Co | Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques |
| CN100525766C (zh) | 1997-06-02 | 2009-08-12 | 詹森药业有限公司 | 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物 |
| WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| EP1031563B1 (en) | 1997-09-30 | 2005-12-28 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
| GB9726229D0 (en) | 1997-12-12 | 1998-02-11 | Zeneca Ltd | Resolution of chiral amines |
| US6172061B1 (en) | 1997-12-19 | 2001-01-09 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
| US6607799B1 (en) | 1998-10-15 | 2003-08-19 | 3M Innovative Properties Company | Surgical dressing with delivery system and method of manufacture |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| US6635278B1 (en) | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| BR0010655A (pt) | 1999-03-24 | 2002-02-13 | Anormed Inc | Compostos heterocìclicos para ligação ao receptor de quimiocina |
| EP1228065A1 (en) | 1999-11-08 | 2002-08-07 | Wyeth | (indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CA2419224A1 (en) | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| US6835731B2 (en) | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| PT1317451E (pt) | 2000-09-15 | 2006-12-29 | Anormed Inc | Compostos heterocíclicos que se ligam a receptores de quimioquinas |
| MXPA03005152A (es) | 2000-12-11 | 2004-10-14 | Tularik Inc | Antogonista de cxcr3. |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| ES2380009T3 (es) | 2001-07-31 | 2012-05-07 | Genzyme Global S.A.R.L. | Métodos para movilizar las células madre/progenitoras |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| WO2003022785A2 (en) | 2001-09-12 | 2003-03-20 | Anormed Inc. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| CA2467718C (en) | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7491544B2 (en) | 2002-05-20 | 2009-02-17 | New York University | Chiral piperidine and quinucledine ligands |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| WO2004052862A1 (ja) | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| AU2004232361A1 (en) | 2003-04-22 | 2004-11-04 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| CN1930127B (zh) | 2004-03-15 | 2012-11-21 | 阿诺麦德股份有限公司 | 用于合成cxcr4拮抗剂的方法 |
| EP1742936A2 (en) * | 2004-04-13 | 2007-01-17 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| US20080096861A1 (en) | 2004-08-02 | 2008-04-24 | Smithkline Beecham Corporation | Chemical Compounds |
| CA2577100A1 (en) | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
| JP2008511669A (ja) | 2004-09-02 | 2008-04-17 | スミスクライン ビーチャム コーポレーション | 化合物 |
| WO2006036816A2 (en) | 2004-09-24 | 2006-04-06 | Smithkline Beecham Corporation | Chemical compounds |
| TW200619206A (en) | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US20090093454A1 (en) | 2005-03-04 | 2009-04-09 | Kristjan Gudmundsson | Chemical Compounds |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20090203533A1 (en) | 2005-07-08 | 2009-08-13 | Siemens Medicals Solutions Diagnositcs Gmbh | Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy |
| US20080214562A1 (en) | 2005-07-11 | 2008-09-04 | Kristjan Gudmundsson | Chemical Compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007015074A1 (en) | 2005-08-02 | 2007-02-08 | Ineos Europe Limited | Diene polymerisation |
| CA2619828A1 (en) | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
| EP1919872A4 (en) | 2005-08-31 | 2009-08-05 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| US20070123538A1 (en) | 2005-11-30 | 2007-05-31 | Schering Corporation | Compositions comprising a combination of CCR5 and CXCR4 antagonists |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| PE20070946A1 (es) | 2006-01-25 | 2007-10-16 | Smithkline Beecham Corp | COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4) |
| JP2009524689A (ja) * | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
| GB0605786D0 (en) | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| CN101466376A (zh) | 2006-06-12 | 2009-06-24 | 辉瑞产品公司 | 用于提高免疫重建并治疗hiv患者的机会感染的ccr5拮抗剂 |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| US20100298314A1 (en) | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1974729A1 (en) * | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| CN101855222A (zh) * | 2007-05-10 | 2010-10-06 | 通用电气健康护理有限公司 | 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2009023179A2 (en) | 2007-08-10 | 2009-02-19 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
| US20110070657A1 (en) | 2007-08-17 | 2011-03-24 | The General Hospital Corporation | Detecting ions and measuring ion concentrations |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| CA2709883A1 (en) | 2007-12-19 | 2009-06-25 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| CN102088993A (zh) | 2008-03-20 | 2011-06-08 | 卡罗勒斯治疗公司 | 炎症的治疗方法 |
| AU2009228034A1 (en) | 2008-03-28 | 2009-10-01 | Altiris Therapeutics | Chemokine receptor modulators |
| WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP2010016628A (ja) | 2008-07-03 | 2010-01-21 | Canon Inc | 画像処理装置及び画像処理方法 |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| EP2482805B1 (en) | 2009-09-28 | 2014-11-19 | Zenbury International Limited | Pharmaceutical composition |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US20110293686A1 (en) | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| CA2706292A1 (en) | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| US9155723B2 (en) | 2010-06-28 | 2015-10-13 | The General Hospital Corporation | Anti-CXCR4 as a sensitizer to cancer therapeutics |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| US9267934B2 (en) | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
| CN103201261A (zh) | 2010-11-10 | 2013-07-10 | 埃科特莱茵药品有限公司 | 用作为食欲素受体拮抗剂的内酰胺衍生物 |
| EP3153510B1 (en) | 2010-12-03 | 2020-05-06 | Emory University | Fused azines as chemokine cxcr4 receptor modulators and uses related thereto |
| JP6076913B2 (ja) * | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | 癌からの転移を阻害する方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN103476410B (zh) | 2011-01-11 | 2020-02-21 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| RU2638802C2 (ru) | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| AR087364A1 (es) | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
| AU2012314943B9 (en) | 2011-09-26 | 2017-06-08 | Merck Patent Gmbh | Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| JP2015503624A (ja) | 2012-01-12 | 2015-02-02 | ギリアード サイエンシーズ， インコーポレイテッド | 医薬組成物およびその調製方法 |
| EP2922861A4 (en) | 2012-11-26 | 2016-09-14 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
| US10064826B2 (en) | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
| KR20220041957A (ko) * | 2013-03-15 | 2022-04-01 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 항-egfr 항체 약물 접합체 제형 |
| WO2014197680A1 (en) | 2013-06-05 | 2014-12-11 | Salk Institute For Biological Studies | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| CA2920377A1 (en) | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| CA3206628A1 (en) | 2013-09-12 | 2015-03-19 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| WO2015143092A1 (en) | 2014-03-18 | 2015-09-24 | The Research Foundation For The State University Of New York | Therapeutic agent for treating tumors |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| EP3157921A1 (en) * | 2014-06-23 | 2017-04-26 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
| DK3169341T3 (da) | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| SG11201704756YA (en) | 2014-12-12 | 2017-07-28 | Commw Scient Ind Res Org | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| EP3307778A1 (en) | 2015-06-12 | 2018-04-18 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| US10379661B2 (en) | 2015-09-25 | 2019-08-13 | Samsung Electronics Co., Ltd. | Coordinate measuring apparatus and coordinate measuring system having the same |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| PL3393468T3 (pl) | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
| CA3010617A1 (en) | 2016-01-22 | 2017-07-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES3014978T3 (en) | 2016-04-14 | 2025-04-28 | Creatv Microtech Inc | Methods of using pd-l1 expression in treatment decisions for cancer therapy |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| JP2020525427A (ja) | 2017-06-21 | 2020-08-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置するための方法 |
| US20210349099A1 (en) | 2017-11-07 | 2021-11-11 | X4 Pharmaceuticals, Inc. | Cancer biomarkers and methods of use thereof |
| WO2019126106A1 (en) | 2017-12-19 | 2019-06-27 | X4 Pharmaceuticals, Inc. | Acyclic cxcr4 inhibitors and uses thereof |
| JP2021521439A (ja) | 2018-04-13 | 2021-08-26 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がん血清バイオマーカーおよびその使用方法 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
-
2017
- 2017-06-21 ES ES17816163T patent/ES2870920T3/es active Active
- 2017-06-21 CN CN202310296466.XA patent/CN116554168B/zh active Active
- 2017-06-21 WO PCT/US2017/038609 patent/WO2017223239A1/en not_active Ceased
- 2017-06-21 CA CA3027498A patent/CA3027498A1/en active Pending
- 2017-06-21 EP EP20212271.9A patent/EP3808748A1/en active Pending
- 2017-06-21 JP JP2018566969A patent/JP7054529B2/ja active Active
- 2017-06-21 CN CN201780048803.6A patent/CN109562106B/zh active Active
- 2017-06-21 EP EP17816163.4A patent/EP3471727B1/en active Active
- 2017-06-21 US US16/311,020 patent/US10759796B2/en active Active
-
2020
- 2020-07-27 US US16/939,723 patent/US11306088B2/en active Active
-
2022
- 2022-03-14 US US17/654,722 patent/US11780837B2/en active Active
- 2022-03-28 JP JP2022051875A patent/JP7402549B2/ja active Active
-
2023
- 2023-09-12 US US18/465,823 patent/US20240150350A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7054529B2 (ja) | 2022-04-14 |
| EP3471727A4 (en) | 2019-10-09 |
| CA3027498A1 (en) | 2017-12-28 |
| CN116554168A (zh) | 2023-08-08 |
| CN109562106B (zh) | 2023-03-21 |
| JP2022076020A (ja) | 2022-05-18 |
| CN116554168B (zh) | 2025-09-23 |
| US20200123150A1 (en) | 2020-04-23 |
| US20210047320A1 (en) | 2021-02-18 |
| US11780837B2 (en) | 2023-10-10 |
| US20220372032A1 (en) | 2022-11-24 |
| JP7402549B2 (ja) | 2023-12-21 |
| EP3471727B1 (en) | 2020-12-09 |
| EP3471727A1 (en) | 2019-04-24 |
| WO2017223239A1 (en) | 2017-12-28 |
| US11306088B2 (en) | 2022-04-19 |
| US10759796B2 (en) | 2020-09-01 |
| JP2019518767A (ja) | 2019-07-04 |
| US20240150350A1 (en) | 2024-05-09 |
| EP3808748A1 (en) | 2021-04-21 |
| CN109562106A (zh) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2870920T3 (es) | Inhibidores de CXCR4 y usos de los mismos | |
| JP6994767B2 (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| JP7084624B2 (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| TW202108571A (zh) | Tead抑制劑及其用途 | |
| EP4323066A1 (en) | Mek inhibitors and uses thereof | |
| EP3846793B1 (en) | Eif4e inhibitors and uses thereof | |
| ES2987356T3 (es) | Compuestos antiproliferación y usos de los mismos | |
| WO2022187849A1 (en) | Salinomycin derivatives and uses thereof | |
| WO2020264292A1 (en) | Cxcr4 inhibitors and uses thereof | |
| HK40050670A (en) | Substituted piperidines as cxcr4-inhibitors | |
| HK40006048A (en) | Cxcr4 inhibitors and uses thereof | |
| HK40006048B (en) | Cxcr4 inhibitors and uses thereof | |
| EA047483B1 (ru) | Ингибиторы tead и их применения |